Methotrexate hydrate
Based on 80 publication(s) in Google Scholar
Methotrexate hydrate (Amethopterin hydrate; CL14377 hydrate; WR19039 hydrate) is an orally active antifolate (Antifolate). Methotrexate hydrate inhibits dihydrofolate reductase (DHFR), blocks tetrahydrofolate production, suppresses purine/pyrimidine synthesis and transmethylation, and causes intracellular accumulation of AICAR. Methotrexate hydrate promotes extracellular adenosine release, regulates the cytokine network, and inhibits the alarmin function of HMGB1. Methotrexate hydrate induces apoptosis and cytotoxicity, upregulates the expression of iNOS and COX-2, suppresses hippocampal neurogenesis, and induces pulmonary fibrosis. Methotrexate hydrate is used in the research of various immune and inflammation-related diseases such as arthritis, psoriasis, systemic lupus erythematosus, as well as pulmonary fibrosis and breast cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.66%
- CAS No.: 133073-73-1
- Formule: C20H22N8O5.xH2O
-
Stockage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
HY-10586
5-Azacytidine
-
HY-B0146
Verteporfin
-
HY-10981
Lenvatinib
-
HY-10583
Y-27632 dihydrochloride
-
HY-17565
Bleomycin sulfate
-
HY-K2014
PEI Transfection Reagent
-
HY-B0083
Leflunomide
-
HY-13568
Benoxaprofen
-
HY-14519A
Methotrexate disodium
-
HY-14518
Aminopterin
-
HY-110382
Cyclic-di-GMP disodium
-
HY-B0273
Sulfadiazine
Publications Citing Use of MedChemExpress (MCE) Methotrexate hydrate
More- Mol Cancer. 2024 Apr 29;23(1):86. [Abstract]
- Mol Cancer. 2024 Jan 10;23(1):12. [Abstract]
- Adv Mater. 2025 Dec 12:e13952. [Abstract]
- Adv Mater. 2025 Jul 4:e2505231. [Abstract]
- Nat Commun. 2025 Feb 28;16(1):2071. [Abstract]
- J Adv Res. 2025 Aug:74:609-620. [Abstract]
- Redox Biol. 2025 Feb:79:103482. [Abstract]
- J Nanobiotechnology. 2024 Mar 3;22(1):89. [Abstract]
- J Exp Clin Cancer Res. 2024 Dec 26;43(1):330. [Abstract]
- J Clin Invest. 2023 Jul 3;133(13):e169993. [Abstract]
- Cell Rep Med. 2025 Apr 15;6(4):102053. [Abstract]
- Mol Biomed. 2025 Nov 21;6(1):114. [Abstract]
- Cell Death Dis. 2025 Nov 24;16(1):852. [Abstract]
- Cell Death Dis. 2025 Nov 24;16(1):856. [Abstract]
- Cell Death Dis. 2024 May 20;15(5):349. [Abstract]
- Cell Death Dis. 2020 Nov 12;11(11):976. [Abstract]
- Small. 2022 Jul;18(30):e2202337. [Abstract]
- Phytomedicine. 2026 Jan:150:157731. [Abstract]
- Phytomedicine. 2022 Jun;100:154068. [Abstract]
- J Pharm Anal. 2022 Dec;12(6):879-888. [Abstract]
- Acta Biomater. 2025 Aug 27:S1742-7061(25)00640-3. [Abstract]
- Acta Pharmacol Sin. 2025 Jun;46(6):1733-1741. [Abstract]
- Acta Pharmacol Sin. 2021 Jan;42(1):108-114. [Abstract]
- Biomater Res. 2025 Sep 3:29:0245. [Abstract]
- EMBO Mol Med. 2025 Oct 13. [Abstract]
- EMBO Mol Med. 2022 Mar 7;14(3):e14552. [Abstract]
- Cell Rep. 2025 Mar 25;44(4):115466. [Abstract]
- Sci Data. 2024 Sep 19;11(1):1024. [Abstract]
- Sci Signal. 2024 Nov 26;17(864):eadp1375. [Abstract]
- J Ethnopharmacol. 2026 Apr 24:361:121230. [Abstract]
- Ecotoxicol Environ Saf. 2025 Nov 15:307:119433. [Abstract]
- Cells. 2026 Jun 11;15(12):1070. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Commun Biol. 2022 Jun 23;5(1):619. [Abstract]
- Eur J Pharmacol. 2023 Dec 15:961:176162. [Abstract]
- Int Immunopharmacol. 2025 Jun 26:159:114894. [Abstract]
- Int Immunopharmacol. 2025 May 27:156:114735. [Abstract]
- Int Immunopharmacol. 2024 Jun 15:134:112183. [Abstract]
- Int Immunopharmacol. 2023 Nov 15;125(Pt B):111175. [Abstract]
- Int Immunopharmacol. 2023 Feb:115:109689. [Abstract]
- Arthritis Res Ther. 2022 Jan 19;24(1):27. [Abstract]
- ACS Omega. 2026 Jan 21;11(4):5853-5864. [Abstract]
- ACS Omega. 2025 Oct 29;10(44):52562-52575. [Abstract]
- Toxicology. 2020 May 15:437:152445. [Abstract]
- Eur J Pharm Sci. 2025 Nov 1:214:107296. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Mediators Inflamm. 2024 Dec 5:2024:1995952. [Abstract]
- Sci Rep. 2024 Oct 31;14(1):26224. [Abstract]
- Sci Rep. 2018 Jun 21;8(1):9472. [Abstract]
- Cancers (Basel). 2022 Oct 19;14(20):5127. [Abstract]
- Cancers. 2019 Oct 25;11(11):1654. [Abstract]
- J Cell Mol Med. 2026 Apr;30(7):e71101. [Abstract]
- Rheumatology (Oxford). 2025 Aug 13:keaf437. [Abstract]
- Antiviral Res. 2026 Jun:250:106417. [Abstract]
- Lung. 2024 Nov 27;203(1):4. [Abstract]
- Antimicrob Agents Chemother. 2026 Jul;70(7):e0196025. [Abstract]
- Chem Res Toxicol. 2025 Feb 17;38(2):281-295. [Abstract]
- J Biol Chem. 2019 Dec 27;294(52):20084-20096. [Abstract]
- Biotechnol Bioeng. 2021 Dec;118(12):4687-4698. [Abstract]
- Mol Immunol. 2025 Apr 16:182:83-95. [Abstract]
- Dis Model Mech. 2023 Mar 1;16(3):dmm049769. [Abstract]
- J Bone Oncol. 2021 Sep 20:30:100391. [Abstract]
- Micromachines. 2021 Jun 10;12(6):681. [Abstract]
- Biochem Biophys Rep. 2021 Nov 26:28:101177. [Abstract]
- Plasma Process Polym. 2021 Feb 12.
- Int J Immunopathol Pharmacol. 2025 Jan-Dec:39:3946320251348715. [Abstract]
- Anticancer Res. 2024 Oct;44(10):4213-4218. [Abstract]
- Anticancer Res. 2024 Jul;44(7):2787-2792. [Abstract]
- bioRxiv. 2026 May 6.
- bioRxiv. 2025 Nov 20.
- SSRN. 2025 Oct 10.
- Patent. US20250235423A1.
- Authorea. 2025 Jan 03.
- Guidelines and Standards in Chinese Medicine. 2024 Dec.
- Biomed Pharmacother. 2024 Sep:178:117167. [Abstract]
- Research Square Preprint. 2023 Dec 4.
- Research Square Preprint. 2023 Dec 1.
- Queen’s University. 2021 Oct.
- Oncotarget. 2017 Dec 2;8(68):112313-112329. [Abstract]
- Patent. US20170128439A1.
Customer Validation & Images
-
Cell Imaging/Staining
-
RT-PCR
-
Cell Proliferation/Viability Assay
-
Cell Migration/Invasion Assay
-
Cell Proliferation/Viability Assay
Activité biologique
|
COX-2 |
IL-8 |
iNOS |
Methotrexate hydrate at high concentrations stimulates adenosine secretion of endothelial cells, fibroblasts and peripheral blood monocytes, and this effect is amplified under metabolic stress; it further modulates macrophage function through adenosine and suppresses peripheral blood mononuclear cells from producing immunoglobulins, rheumatoid factors and spontaneous IL-8, which may be attributed to the reduction of intracellular polyamine levels[1].
Methotrexate (MTX) (0.01-100 μM; 72 h) hydrate induces dose-dependent cytotoxicity in primary mouse alveolar epithelial cells (MAEC) and primary mouse lung fibroblasts (MLF)[4].
Methotrexate (1 μM; 12-48 h) hydrate induces significant time-dependent apoptosis in primary mouse alveolar epithelial cells (MAEC), but exerts no significant pro-apoptotic effect on primary mouse lung fibroblasts (MLF) under the same conditions[4].
Methotrexate (0.5-5 μM; 24 h) hydrate dose-dependently enhances cytotoxicity and reduces cell viability in FM3A breast cancer cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Methotrexate (3 mg/kg; p.o.; daily; days 21-35) hydrate induces pulmonary fibrosis in male C57BL/6J mice in a time-dependent manner[4].
Methotrexate (40 mg/kg; i.p.; single dose) hydrate induces hippocampal dysfunction in both FM3A-inoculated breast cancer mice and tumor-free healthy mice, including significant depression-like behaviors, cognitive impairment, reduced hippocampal neurogenesis, and upregulated expression of pro-inflammatory enzymes[5].
Methotrexate (MTX) (2 mg/kg; i.p.; once weekly for 5 consecutive weeks) hydrate is effective against Freund's complete adjuvant-induced arthritis[6].
Methotrexate (1 mg/kg, intraperitoneal injection, once a week for 5 weeks) hydrate combined with Curcumin (HY-N0005, 30 mg/kg and 100 mg/kg, intraperitoneal injection, three times a week for 5 weeks) exhibits remarkable anti-arthritic effects and protective activity against hematotoxicity[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 133073-73-1
-
Appearance Solid
-
Formule C20H22N8O5.xH2O
-
Color Yellow to orange
-
SMILES
NC1=NC(N)=C2C(N=CC(CN(C)C3=CC=C(C(N[C@@H](CCC(O)=O)C(O)=O)=O)C=C3)=N2)=N1.O.[x]
-
Synonyms
Amethopterin hydrate; CL14377 hydrate; WR19039 hydrate
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (80)
-
Journal Impact Factor
-
Most Recent
-
Mol Cancer
2024 Apr 29;23(1):86. PMID: 38685067 -
Mol Cancer
Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. [Abstract]2024 Jan 10;23(1):12. PMID: 38200517 -
Adv Mater
3D Bioprinted Human Synovium-Cartilage Models Mimic Rheumatoid Arthritis Microenvironment and Recapitulate In Vivo Therapeutic Responses. [Abstract]2025 Dec 12:e13952. PMID: 41388589 -
Adv Mater
Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local Adhesion and Drug Release to Bladder Cancers. [Abstract]2025 Jul 4:e2505231. PMID: 40611758 -
Nat Commun
ACSS2 drives senescence-associated secretory phenotype by limiting purine biosynthesis through PAICS acetylation. [Abstract]2025 Feb 28;16(1):2071. PMID: 40021646
Methotrexate hydrate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 28;16(1):2071. [Abstract]
OIS cells were infected with shCtrl orshACSS2 followed by selection and treated with or without MTX (40 μM) for 2 days. Cells were stained with γH2AX.
Methotrexate hydrate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 28;16(1):2071. [Abstract]
OIS cells were infected with shCtrl orshACSS2 followed by selection and treated with or without MTX (40 μM) for 2 days. The expression of SASP genes was analysed by qRT–PCR.
-
J Adv Res
Columbianadin ameliorates rheumatoid arthritis by attenuating synoviocyte hyperplasia through targeted vimentin to inhibit the VAV2/Rac-1 signaling pathway. [Abstract]2025 Aug:74:609-620. PMID: 39369957
Methotrexate hydrate purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Aug:74:609-620. [Abstract]
The cell viability of MH7A cells treated with methotrexate (1 μM) for 24 h was determined by the CCK-8 method.
Methotrexate hydrate purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Aug:74:609-620. [Abstract]
The cell migration of MH7A cells treated with methotrexate (1 μM) for 24 h.
-
Redox Biol
Therapeutic potential of monomethyl fumarate and aluminum ion combination in alleviating inflammation and oxidative stress in psoriasis. [Abstract]2025 Feb:79:103482. PMID: 39736200 -
J Nanobiotechnology
EphA2-specific microvesicles derived from tumor cells facilitate the targeted delivery of chemotherapeutic drugs for osteosarcoma therapy. [Abstract]2024 Mar 3;22(1):89. PMID: 38433190 -
J Exp Clin Cancer Res
OTULIN confers cisplatin resistance in osteosarcoma by mediating GPX4 protein homeostasis to evade the mitochondrial apoptotic pathway. [Abstract]2024 Dec 26;43(1):330. PMID: 39721999 -
J Clin Invest
Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3/4-COMPASS epigenetic regulator mutations. [Abstract]2023 Jul 3;133(13):e169993. PMID: 37252797
Methotrexate hydrate purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2023 Jul 3;133(13):e169993. [Abstract]
A CellTiter-Glo® luminescent cell viability assay was performed on CAL51 WT and MLL4 KO cells, which were treated with 0, 0.04, or 0.4 μM Methotrexate (MTX) in the presence of H2O, 50 μM thymidine, or 50 μM inosine.
-
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 15;6(4):102053. PMID: 40187357 -
Mol Biomed
A single non-coding SNP in FPGS modulates folate drug efficacy in acute lymphoblastic leukemia: data-driven exploration and experimental validation. [Abstract]2025 Nov 21;6(1):114. PMID: 41269429 -
Cell Death Dis
Downregulation of ZFP36L1 contributes to methotrexate resistance in osteosarcoma through enhanced NHEJ DNA repair mechanisms. [Abstract]2025 Nov 24;16(1):852. PMID: 41285712 -
Cell Death Dis
2025 Nov 24;16(1):856. PMID: 41285805 -
Cell Death Dis
Deprivation of methionine inhibits osteosarcoma growth and metastasis via C1orf112-mediated regulation of mitochondrial functions. [Abstract]2024 May 20;15(5):349. PMID: 38769167 -
Cell Death Dis
2020 Nov 12;11(11):976. PMID: 33184290 -
Small
DNA Base Pairing-Inspired Supramolecular Nanodrug Camouflaged by Cancer-Cell Membrane for Osteosarcoma Treatment. [Abstract]2022 Jul;18(30):e2202337. PMID: 35780479 -
Phytomedicine
Paeoniflorin derivative ameliorates methotrexate resistance in treating rheumatoid arthritis through targeting GRK2-A2AAR axis. [Abstract]2026 Jan:150:157731. PMID: 41447845 -
Phytomedicine
Geniposide alleviates VEGF-induced angiogenesis by inhibiting VEGFR2/PKC/ERK1/2-mediated SphK1 translocation. [Abstract]2022 Jun;100:154068. PMID: 35358930 -
J Pharm Anal
A highly efficient protein corona-based proteomic analysis strategy for the discovery of pharmacodynamic biomarkers. [Abstract]2022 Dec;12(6):879-888. PMID: 36605576 -
Acta Biomater
2025 Aug 27:S1742-7061(25)00640-3. PMID: 40882907 -
Acta Pharmacol Sin
Bardoxolone displays potent activity against triple negative breast cancer by inhibiting the TRIP13/STAT3 circuit. [Abstract]2025 Jun;46(6):1733-1741. PMID: 39939802 -
Acta Pharmacol Sin
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]2021 Jan;42(1):108-114. PMID: 32398685 -
Biomater Res
Albumin Nanocages with Methotrexate and Chondroitin Sulfate as a Dual pH/GSH-Responsive Tumor Targeting Nanomedicine for Synergistic Cancer Therapy. [Abstract]2025 Sep 3:29:0245. PMID: 40908968 -
EMBO Mol Med
Glycine decarboxylase advances IgA nephropathy by boosting mesangial cell proliferation through the pyrimidine pathway. [Abstract]2025 Oct 13. PMID: 41083822 -
EMBO Mol Med
A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis. [Abstract]2022 Mar 7;14(3):e14552. PMID: 35174975 -
Cell Rep
Structural basis for the reversal of human MRP4-mediated multidrug resistance by lapatinib. [Abstract]2025 Mar 25;44(4):115466. PMID: 40138312 -
Sci Data
High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma. [Abstract]2024 Sep 19;11(1):1024. PMID: 39300112 -
Sci Signal
Coordination between the eIF2 kinase GCN2 and p53 signaling supports purine metabolism and the progression of prostate cancer. [Abstract]2024 Nov 26;17(864):eadp1375. PMID: 39591412 -
J Ethnopharmacol
Kai-Xin-San alleviates Alzheimer's disease by targeting the DHFR-mediated folate-mitochondrial axis. [Abstract]2026 Apr 24:361:121230. PMID: 41548619 -
Ecotoxicol Environ Saf
PPARγ-responsive luciferase reporter system for high-throughput screening of chemical toxins with potential pulmonary fibrosis effects. [Abstract]2025 Nov 15:307:119433. PMID: 41273832 -
Cells
Structure-Based Virtual Screening and Mechanistic Characterization of Methotrexate and Selinexor as Potent Anti-Melanogenic Agents via Multi-Pathway Suppression of MITF. [Abstract]2026 Jun 11;15(12):1070. PMID: 42346097 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Commun Biol
Serine hydroxymethyltransferase as a potential target of antibacterial agents acting synergistically with one-carbon metabolism-related inhibitors. [Abstract]2022 Jun 23;5(1):619. PMID: 35739195 -
Eur J Pharmacol
Lycorine eliminates B-cell acute lymphoblastic leukemia cells by targeting PSAT1 through the serine/glycine metabolic pathway. [Abstract]2023 Dec 15:961:176162. PMID: 37951487 -
Int Immunopharmacol
Isorhapontigenin suppresses inflammation, proliferation and aggressiveness of rheumatoid arthritis fibroblast-like synoviocytes by targeting farnesyl diphosphate synthase. [Abstract]2025 Jun 26:159:114894. PMID: 40412131 -
Int Immunopharmacol
Regulation of P-glycoprotein through CaMKII/cPLA2 pathway in lymphocytes for treating refractory rheumatoid arthritis by manidipine. [Abstract]2025 May 27:156:114735. PMID: 40294472 -
Int Immunopharmacol
Cornuside alleviates psoriasis-like skin lesions in mice by relieving inflammatory effects. [Abstract]2024 Jun 15:134:112183. PMID: 38705031 -
Int Immunopharmacol
Herbal compound cepharanthine attenuates inflammatory arthritis by blocking macrophage M1 polarization. [Abstract]2023 Nov 15;125(Pt B):111175. PMID: 37976601 -
Int Immunopharmacol
Iso-seco-tanapartholide induces p62 covalent oligomerization to activate KEAP1-NRF2 redox pathway in rheumatoid arthritis. [Abstract]2023 Feb:115:109689. PMID: 36621330 -
Arthritis Res Ther
Penfluridol targets acid sphingomyelinase to inhibit TNF signaling and is therapeutic against inflammatory autoimmune diseases. [Abstract]2022 Jan 19;24(1):27. PMID: 35045889 -
ACS Omega
ROS-Scavenging Bamboo-Derived Carbon Dot-Methotrexate Nanocomposite Ameliorates Rheumatoid Arthritis through Dual Therapeutic Mechanisms. [Abstract]2026 Jan 21;11(4):5853-5864. PMID: 41658163 -
ACS Omega
Association Study of OATP1B3 Polymorphisms on Hepatic Uptake and Drug-Drug Interaction In Vitro. [Abstract]2025 Oct 29;10(44):52562-52575. PMID: 41244417 -
Toxicology
Drug interaction study of flavonoids toward OATP1B1 and their 3D structure activity relationship analysis for predicting hepatoprotective effects. [Abstract]2020 May 15:437:152445. PMID: 32259555 -
Eur J Pharm Sci
Repurposing of FDA-approved drugs by targeting SIRT2 to alleviate inflammatory response and kidney injury. [Abstract]2025 Nov 1:214:107296. PMID: 41022315 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Mediators Inflamm
Peptide BG From Bitter Gourd (Momordica Charantia) Improves Adjuvant-Induced Arthritis by Modulating the Necroptosis/Neutrophil Extracellular Traps/Inflammation Axis and the Gut Microbiota. [Abstract]2024 Dec 5:2024:1995952. PMID: 39669913 -
Sci Rep
High expression of LncRNA HOTAIR is a risk factor for temozolomide resistance in glioblastoma via activation of the miR-214/β-catenin/MGMT pathway. [Abstract]2024 Oct 31;14(1):26224. PMID: 39482401 -
Sci Rep
A widely-applicable high-throughput cellular thermal shift assay (CETSA) using split Nano Luciferase. [Abstract]2018 Jun 21;8(1):9472. PMID: 29930256 -
Cancers (Basel)
Association between Dysfunction of the Nucleolar Stress Response and Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia. [Abstract]2022 Oct 19;14(20):5127. PMID: 36291909 -
Cancers
2019 Oct 25;11(11):1654. PMID: 31717700 -
J Cell Mol Med
2026 Apr;30(7):e71101. PMID: 41896195 -
Rheumatology (Oxford)
Autophagy inhibitors block pathogenic NET release in immune-mediated inflammatory disease without impairing host defence. [Abstract]2025 Aug 13:keaf437. PMID: 40802538 -
Antiviral Res
Repurposing screen using a robust human rhinovirus infectious clone identifies pyrvinium pamoate with antiviral activity. [Abstract]2026 Jun:250:106417. PMID: 42025967 -
Lung
Disulfiram Alleviates MTX-Induced Pulmonary Fibrosis by Inhibiting EMT in Type 2 Alveolar Epithelial Cells. [Abstract]2024 Nov 27;203(1):4. PMID: 39601871 -
Antimicrob Agents Chemother
Pralatrexate is a potent pan-serotype human adenovirus inhibitor through suppression of dihydrofolate reductase. [Abstract]2026 Jul;70(7):e0196025. PMID: 42206914 -
Chem Res Toxicol
Inhibitory Effects of Alkaloids on OATP1B1 In Vitro and In Vivo: Prediction for Food/Herb-Drug Interactions and Hepatoprotective Effects Based on Structure-Activity Relationships. [Abstract]2025 Feb 17;38(2):281-295. PMID: 39899883 -
J Biol Chem
A technique for delineating the unfolding requirements for substrate entry into retrotranslocons during endoplasmic reticulum-associated degradation. [Abstract]2019 Dec 27;294(52):20084-20096. PMID: 31748412 -
Biotechnol Bioeng
An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]2021 Dec;118(12):4687-4698. PMID: 34478150 -
Mol Immunol
Methotrexate loaded extracellular vesicles attenuate periodontitis by suppressing ACSL1 and promoting anti-inflammatory macrophage. [Abstract]2025 Apr 16:182:83-95. PMID: 40245705 -
Dis Model Mech
A Drosophila chemical screen reveals targeting MEK and DGKa mitigates Ras-driven polarity-impaired tumour growth. [Abstract]2023 Mar 1;16(3):dmm049769. PMID: 36861754 -
J Bone Oncol
Identification of GPC3 mutation and upregulation in a multidrug resistant osteosarcoma and its spheroids as therapeutic target. [Abstract]2021 Sep 20:30:100391. PMID: 34611509 -
Micromachines
2021 Jun 10;12(6):681. PMID: 34200752 -
Biochem Biophys Rep
Histone H3 lysine-trimethylation markers are decreased by recombinant methioninase and increased by methotrexate at concentrations which inhibit methionine-addicted osteosarcoma cell proliferation. [Abstract]2021 Nov 26:28:101177. PMID: 34877414 -
-
Int J Immunopathol Pharmacol
Cucurbitacin B inhibits Th17 cell differentiation via the suppression of the JAK/STAT pathway and alleviates collagen-induced arthritis in mice. [Abstract]2025 Jan-Dec:39:3946320251348715. PMID: 40518910 -
Anticancer Res
Loss of Malignancy of Super-Methotrexate-resistant Osteosarcoma Cells Is Associated With an Increase of Methylated Histone Marks H3K9me3 and H3K27me3. [Abstract]2024 Oct;44(10):4213-4218. PMID: 39348992 -
Anticancer Res
Reduced Malignancy of Super Methotrexate-resistant Osteosarcoma Cells With Dihydrofolate Reductase Amplification Despite Paradoxical Gain of Oncogenic PI3K/AKT/mTOR and c-MYC expression. [Abstract]2024 Jul;44(7):2787-2792. PMID: 38925854 -
-
-
-
-
-
-
Biomed Pharmacother
Characterization of a deazaflavin analog as a potent inhibitor of multidrug resistance-associated protein 1. [Abstract]2024 Sep:178:117167. PMID: 39032285 -
-
-
-
Oncotarget
Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease. [Abstract]2017 Dec 2;8(68):112313-112329. PMID: 29348827 -
Solvant et solubilité
DMSO : 10 mg/mL (ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 1 mg/mL; Clear solution
This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (276 KB)
-
SDS (644 KB)
- English - EN (644 KB)
- Français - FR (644 KB)
- Deutsch - DE (644 KB)
- Norwegian - NO (644 KB)
- Español - ES (644 KB)
- Swedish - SV (644 KB)
- Italian - IT (644 KB)
- Korean - KR (644 KB)
- Portuguese - PT (644 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Cronstein BN, et al. The mechanism of action of methotrexate. Rheumatic diseases clinics of North America. 1997 Nov;23(4):739-55. [Content Brief]
[2]. Bedoui Y, et al. Methotrexate an Old Drug with New Tricks. International journal of molecular sciences. 2019 Oct 10;20(20):5023. [Content Brief]
[4]. Ohbayashi M, et al. Induction of pulmonary fibrosis by methotrexate treatment in mice lung in vivo and in vitro. The Journal of toxicological sciences. 2010 Oct;35(5):653-61. [Content Brief]
[5]. Yang M, et al. Acute treatment with methotrexate induces hippocampal dysfunction in a mouse model of breast cancer. Brain research bulletin. 2012 Oct 01;89(1-2):50-6. [Content Brief]
[6]. Banji D, et al. Evaluation of the concomitant use of methotrexate and curcumin on Freund's complete adjuvant-induced arthritis and hematological indices in rats. Indian J Pharmacol. 2011 Sep;43(5):546-50. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Methotrexate hydrate Related Classifications
HY-14519B Related Classifications
Powered by Bioz
- Methotrexate
- 133073-73-1
- Amethopterin
- CL14377
- WR19039
- CL 14377
- CL-14377
- WR 19039
- WR-19039
- Antifolate
- Dihydrofolate reductase (DHFR)
- NO Synthase
- COX
- Interleukin Related
- tetrahydrofolate
- AICAR transformylase
- ROS
- COX-2
- iNOS
- HMGB1 alarmin
- purine/pyrimidine synthesis
- dihydrofolate reductase
- Methotrexate hydrate-polyglutamates
- leukotriene B4
- Inhibitor
- inhibitor
- inhibit